OptimizeRx Corporation OPRX
7.18 USD +0.24 (+3.46%)
As ofNov 18, 2026, 3:16 PM EST
6.95 Day range 7.38
4.54 52-week range 15.59
- YTD
- -41.44%
- 1 year
- -49.15%
News
globenewswire.com OptimizeRx to Participate in the 15th Annual ROTH Technology Conference WALTHAM, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…benzinga.com Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $10 Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
benzinga.com These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results OptimizeRx Corporation (NASDAQ:OPRX) reported upbeat earnings for the third quarter, but lowered its sales guidance on Wednesday.
benzinga.com These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results OptimizeRx beat Q3 earnings and sales estimates but cut FY2026 revenue guidance; shares fell 17.3% as analysts lowered price targets.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…benzinga.com B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $10.5 B. Riley Securities analyst Josh Nichols reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.5.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session. ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their…benzinga.com Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $11 Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $12 to $11.
benzinga.com Why Tetra Tech Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket Tetra Tech shares jumped 8.5% after beating Q4 estimates; Children's Place surged 302%, while Wheeler REIT fell 35.3% premarket.
benzinga.com OptimizeRx Shares Tumble 20% After-Hours: Here's Why OptimizeRx shares tumble 20% after-hours after earnings beat estimates despite lower 2026 revenue guidance.
seekingalpha.com OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript
marketbeat.com What OptimizeRx (OPRX) Said on Its Q3 Earnings Call OptimizeRx NASDAQ: OPRX lowered its 2026 revenue outlook after third-quarter sales fell 17%, even as cost reductions and a favorable product mix helped the healthcare marketing technology company…
zacks.com OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.2 per share a year ago.
benzinga.com OptimizeRx Q3 2026 Earnings Call Transcript OptimizeRx (NASDAQ:OPRX) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock rose 7.1% to $1.66 during Wednesday's after-market session. The market value of their outstanding shares is at $3.5 million. iTonic Holdings (NASDAQ:ITOC)…benzinga.com OptimizeRx Q3 Adj. EPS $0.20 Beats $0.17 Estimate, Sales $21.615M Beat $21.188M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is unchanged from the same period last year. The…
benzinga.com OptimizeRx Lowers FY2026 Sales Guidance from $95.000M-$100.000M to $87.000M-$93.000M vs $96.230M Est OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $95.000 million-$100.000 million to $87.000 million-$93.000 million vs $96.230 million estimate.
globenewswire.com OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
